Aktienanalyse zu Cellectis SA (CLLS)CLLSCellectis SA

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others. It operates in the Healthcare sector.

Cellectis SA is not a good buy right now due to its significant financial struggles and negative sentiment surrounding its strategic shift. The current price is $1.035, which is far below the 52-week high of $5.45, indicating a lack of investor confidence. Additionally, the company's forward P/E is 0, suggesting no earnings growth is expected in the near term. The recent downgrade by Barclays, which set a target price of $1.30, reflects concerns about the company's pivot away from CAR-T therapies, further supporting a sell recommendation.

6 analysts cover CLLS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.